Abstract
Glimepiride sulfonamide (GS) is a drug intermediate to synthesize glimepiride (antidiabetic drug). We hypothesized that GS exerts gluco-regulatory effect because GS is comprised of the structural components of dipeptidyl peptidase-IV (DPP-IV) inhibitors sitagliptin and DPP-728and glimepiride (sulfonylurea based antidiabetic drug).We analyzed the drug-likeness and docking efficiency of GS with DPP-IV using in silico tools. Also DPP-IV inhibition assays were conducted in vitro. Gluco-regulatory potential and parameters of drug safety were evaluated on normal euglycemic and streptozotocin (STZ) induced diabetic rats. We observed strong drug-likeness and DPP-IV binding efficiency of GS. Similarly, profound DPP-IV inhibition was also observed in vitro. Studies on euglycemic and STZ induced diabetic rats revealed antidiabetic potential for GS without significant change in the studied toxicological parameters. Glimepiride sulfonamide has antidiabetic potential mainly through DPP-IV inhibition, but also through insulin stimulation and alpha-amylase inhibition
Keywords: Alanine amino transaminase, alpha-amylase, aspartate aminotransferase, diabetes, dipeptidyl peptidase-IV, insulin, lipid peroxidation, urea.
Current Pharmaceutical Design
Title:Study on Gluco-Regulatory Potential of Glimepiride Sulfonamide Using In silico, In Vitro and In Vivo Approaches
Volume: 20 Issue: 32
Author(s): Hamendra Singh Parmar, Mahesh Kumar Bhinchar, Muskan Bhatia, Nikita Chordia, Ishan Raval, Digvijay Singh Chauhan, E. Manivannan, Rameshwar Jatwa and Anil Kumar
Affiliation:
Keywords: Alanine amino transaminase, alpha-amylase, aspartate aminotransferase, diabetes, dipeptidyl peptidase-IV, insulin, lipid peroxidation, urea.
Abstract: Glimepiride sulfonamide (GS) is a drug intermediate to synthesize glimepiride (antidiabetic drug). We hypothesized that GS exerts gluco-regulatory effect because GS is comprised of the structural components of dipeptidyl peptidase-IV (DPP-IV) inhibitors sitagliptin and DPP-728and glimepiride (sulfonylurea based antidiabetic drug).We analyzed the drug-likeness and docking efficiency of GS with DPP-IV using in silico tools. Also DPP-IV inhibition assays were conducted in vitro. Gluco-regulatory potential and parameters of drug safety were evaluated on normal euglycemic and streptozotocin (STZ) induced diabetic rats. We observed strong drug-likeness and DPP-IV binding efficiency of GS. Similarly, profound DPP-IV inhibition was also observed in vitro. Studies on euglycemic and STZ induced diabetic rats revealed antidiabetic potential for GS without significant change in the studied toxicological parameters. Glimepiride sulfonamide has antidiabetic potential mainly through DPP-IV inhibition, but also through insulin stimulation and alpha-amylase inhibition
Export Options
About this article
Cite this article as:
Parmar Singh Hamendra, Bhinchar Kumar Mahesh, Bhatia Muskan, Chordia Nikita, Raval Ishan, Chauhan Singh Digvijay, Manivannan E., Jatwa Rameshwar and Kumar Anil, Study on Gluco-Regulatory Potential of Glimepiride Sulfonamide Using In silico, In Vitro and In Vivo Approaches, Current Pharmaceutical Design 2014; 20 (32) . https://dx.doi.org/10.2174/1381612820666140318114832
DOI https://dx.doi.org/10.2174/1381612820666140318114832 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure Guided Molecular Docking Assisted Alignment Dependent 3DQSAR Study on Steroidal Aromatase Inhibitors (SAIs) as Anti-breast Cancer Agents
Letters in Drug Design & Discovery Oxidative Stress and the JNK Pathway are Involved in the Development of Type 1 and Type 2 Diabetes
Current Molecular Medicine Nocturnal Hypertension and Chronic Kidney Disease
Current Hypertension Reviews Magnesium and Anaesthesia
Current Drug Targets Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System
Current Pharmaceutical Design The Pharmacology of Diabetic Complications
Current Medicinal Chemistry Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics
Current Cardiology Reviews Future Anti-aldosterone Agents
Current Pharmaceutical Design Microencapsulation for Human Islet Transplantation
Micro and Nanosystems Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer
Current Pharmaceutical Design Management of Statin-Intolerant High-Risk Patients
Current Vascular Pharmacology Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry A Review Study on Prakriti (Body Constitution) Specific Herbal Tea in Diabetes Mellitus
Current Traditional Medicine Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Disparities in Cardiovascular Disease Risk in the United States
Current Cardiology Reviews Anticonvulsant Action and Long-term Effects of Gabapentin
Current Neuropharmacology Direct Renin Inhibition: Promising Treatment in Renoprotection?
Recent Patents on Cardiovascular Drug Discovery Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery